

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA.

Press release

## **Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders**

**Berlin, 27 April 2021** – On 27 April 2021, the Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “company”) resolved, with approval of the Supervisory Board, to increase the company’s share capital through a rights issue using the Authorized Capital 2020/II. The share capital shall be increased from currently EUR 9,852,690.00 by up to EUR 1,970,538.00 to up to EUR 11,823,228.00 by issuing up to 1,970,538 new registered no par value shares of the company against cash contributions.

The subscription price of the new shares was set at EUR 1.10. The new shares will be offered to the company’s shareholders as part of a public offering in Germany by way of indirect subscription rights during the subscription period, which is expected to run from 3 May 2021 to 17 May 2021. The subscription ratio will be 5:1. This means that for each 5 existing shares of the company, a subscription right for 1 new share is allocated. The company will strive to place new shares that are not subscribed during the subscription period with selected investors. M.M.Warburg & CO (AG & Co.) Kommanditgesellschaft auf Aktien is accompanying the transaction.

Deutsche Balaton Aktiengesellschaft, with 22.59% the largest shareholder of Epigenomics AG, has already announced that it will participate in the capital increase.

### **Contact:**

#### **Company**

Epigenomics AG, Geneststraße 5, 10829 Berlin

Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, e-mail: [contact@epigenomics.com](mailto:contact@epigenomics.com)

### **Investor Relations**

IR.on AG, Frederic Hilke, Fabian Kirchmann, Tel +49 221 9140 970, e-mail: [ir@epigenomics.com](mailto:ir@epigenomics.com)

### **Important Notice**

*This publication does not constitute or form part of, and should not be construed as an offer or an invitation to sell, or issue or the solicitation of any offer to buy or subscribe for, any securities. The shares will be solely offered on the basis of the published subscription offer. This publication does, in particular, not constitute an*

*offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of U.S. persons, except that the offered shares may be offered or sold to qualified institutional buyers in reliance on certain exemptions from the registration requirements of the Securities Act and applicable state securities laws. This publication and the information contained herein may not be distributed or sent into the United States, or in any other jurisdiction in which offers or sales of the securities described herein would be prohibited by applicable laws, and should not be distributed to United States persons or by way of publications with a general circulation in the United States. No public offering of the shares is being made in the United States. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or South Africa or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or South Africa. The securities referred to herein have not been and will not be registered under the applicable securities laws of Australia, Canada or Japan.*

## **Forward-Looking Statements**

*This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*